| 1 |
33008144 | Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations. | 2020 Sep 30 |
3 |
| 2 |
30783122 | Insight of Captagon Abuse by Chemogenomics Knowledgebase-guided Systems Pharmacology Target Mapping Analyses. | 2019 Feb 19 |
2 |
| 3 |
31776871 | Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder. | 2019 Dec |
1 |
| 4 |
28473326 | Reduced carboxylesterase 1 is associated with endothelial injury in methamphetamine-induced pulmonary arterial hypertension. | 2017 Aug 1 |
2 |
| 5 |
25998998 | CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. | 2015 Jul |
4 |
| 6 |
23162568 | MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? | 2012 |
1 |
| 7 |
17389081 | Determination of amphetamine, methamphetamine, and hydroxyamphetamine derivatives in urine by gas chromatography-mass spectrometry and its relation to CYP2D6 phenotype of drug users. | 2007 Jan-Feb |
3 |
| 8 |
11707061 | Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. | 2001 |
1 |
| 9 |
10456690 | Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. | 1999 Jul |
1 |
| 10 |
9264312 | Interactions of amphetamine analogs with human liver CYP2D6. | 1997 Jun 1 |
7 |
| 11 |
9833017 | Effect of CYP2D1 inhibition on the behavioural effects of d-amphetamine. | 1997 Jun |
2 |